Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dihon

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Virgo Consumer Health & Wellbeing hires Kirsty McKinnon

Med comms agency strengthens senior team with new personal care sector lead

- PMLiVE

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

Webinar: Understanding the patient journey in China

The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers...

Research Partnership

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Research Partnership

Eli Lilly HQ

Lilly signs cancer pact with Chinese biotech

Marks first major deal between a Western pharma company and a Chinese biotech

- PMLiVE

GSK fires Chinese staff over corruption charges

110 employees reportedly dismissed for misconduct

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

- PMLiVE

UK doctors call on NHS to use Avastin for wet AMD

Controversial practice of using the drug off-label could save the health service £102m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links